Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

被引：0

作者：

N. L. Steele

J. A. Plumb

L. Vidal

J. Tjørnelund

P. Knoblauch

P. Buhl-Jensen

R. Molife

R. Brown

J. S. de Bono

T. R. J. Evans

机构：

[1] Beatson West of Scotland Cancer Centre,Centre for Oncology and Applied Pharmacology

[2] University of Glasgow,undefined

[3] Royal Marsden Hospital,undefined

[4] Topotarget,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2011年 / 67卷

关键词：

Histone deacetylase; Phase-1 trial; Pharmacokinetics; Pharmacodynamics; Bioavailability;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

下载

页码：1273 / 1279

页数：6

共 50 条

[31] Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates
Warren, Katherine E.
McCully, Cindy M.
Dvinge, Henrik
Sehested, Maxwell
Tjornelund, Jette
Lichenstein, Henri S.
Balis, Frank M.
CANCER RESEARCH, 2006, 66 (08)
[32] A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Steele, Nicola L.
Plumb, Jane A.
Vidal, Laura
Tjornelund, Jette
Knoblauch, Poul
Rasmussen, Annie
Ooi, Chean Eng
Buhl-Jensen, Peter
Brown, Robert
Evans, T. R. Jeffry
DeBono, Johann S.
CLINICAL CANCER RESEARCH, 2008, 14 (03) : 804 - 810
[33] PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors
Li, Jingyao
Li, Xiaoyang
Wang, Xue
Hou, Jinning
Zang, Jie
Gao, Shuai
Xu, Wenfang
Zhang, Yingjie
CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (04) : 574 - 584
[34] The histone deacetylase inhibitor PXD101 synergises with established chemotherapeutics to inhibit tumor cell proliferation and upregulate apoptosis in vitro.
Ritchie, J
Tumber, A
Edwards, N
Finn, P
Jensen, PB
Sehested, M
McLaughlin, F
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6105S - 6106S
[35] A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasma
Zhang, Ningning
Goh, Boon Cher
Khoo, Yok Moi
Yeo, Winnie
Lee, How Sung
THERAPEUTIC DRUG MONITORING, 2007, 29 (02) : 231 - 235
[36] The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Anthony Tumber
Laura S. Collins
Kamille Dumong Petersen
Annemette Thougaard
Sanne J. Christiansen
Marielle Dejligbjerg
Peter Buhl Jensen
Maxwell Sehested
James W. A. Ritchie
Cancer Chemotherapy and Pharmacology, 2007, 60 : 275 - 283
[37] The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Tumber, Anthony
Collins, Laura S.
Dumong Petersen, Kamille
Thougaard, Annemette
Christiansen, Sanne J.
Dejligbjerg, Marielle
Buhl Jensen, Peter
Sehested, Maxwell
Ritchie, James W. A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (02) : 275 - 283
[38] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
S. H. Kim
J. G. Kang
C. S. Kim
S.-H. Ihm
M. G. Choi
H. J. Yoo
S. J. Lee
Journal of Endocrinological Investigation, 2018, 41 : 677 - 689
[39] Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells
Kim, S. H.
Kang, J. G.
Kim, C. S.
Ihm, S-H
Choi, M. G.
Yoo, H. J.
Lee, S. J.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2018, 41 (06) : 677 - 689
[40] Pharmacokinetic analysis of the HDAC inhibitor belinostat (PXD-101) and metabolites in patients with hepatic dysfunction
Kiesel, Brian
Parise, Robert
Lin, Yan
Allen, Deborah
Reddy, Guru
Chawla, Shanta
Piekarz, Richard
Ivy, Percy
Kumar, Shivaani
Beumer, Jan H.
CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →